Tamarack Advisers, LP Nektar Therapeutics Transaction History

Tamarack Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 08, 2018	SELL	$57.4 - $108.44 $6.03 Million - $11.4 Million	-105,000 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $10.2 Million - $26.9 Million	-445,000 Reduced 80.91%	105,000 $6.27 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $9.78 Million - $13.2 Million	550,000	550,000 $13.2 Million

142

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $231M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Tamarack Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Tamarack Advisers, LP with notifications on news.